Here is the clinical content regarding .
Body Surface Area (BSA) and varies significantly depending on the underlying condition. 1. Gastroenteritis (Off-Label) For children 6 months to 12 years old, a single oral dose is often considered in emergency settings for mild-to-moderate dehydration or failed oral rehydration. Pediatricians determine the appropriate amount based on the child's weight, usually tailored to whether the child is under 15 kg, between 15 and 30 kg, or over 30 kg. 2. Chemotherapy-Induced Nausea & Vomiting (CINV) Dosing for chemotherapy is more frequent and depends on the child's age or weight. Children 4 to 11 Years: Oral administration occurs roughly 30 minutes before chemotherapy, with possible repeat doses 4 and 8 hours after the first dose, followed by maintenance doses for 1–2 days after treatment. Adolescents (12+ Years): Oral administration occurs roughly 30 minutes before chemotherapy, repeated 8 hours later, then maintenance doses for 1–2 days. Intravenous (IV) Option: IV administration occurs 30 minutes before chemotherapy, repeated 4 and 8 hours after the first dose, based on the child's weight. 3. Post-Operative Nausea & Vomiting (PONV) 1 Month to 12 Years: IV administration is typically weight-based for patients under 40 kg, or a set amount for those over 40 kg. 12 Years and Older: IV or intramuscular (IM) administration occurs before anesthesia or after the procedure. Important Safety Considerations 12 sites Zofran (ondansetron) dosing, indications, interactions ... 1 month-12 years. <40 kg, 0.1 mg/kg IV. >40 kg, 4 mg IV. >12 years. 4 mg IV/IM immediately before anesthesia or after procedure or... Medscape Reference Ondansetron | Drug Index - Pediatric Oncall Ondansetron * Mechanism : Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully c... Pediatric Oncall Ondansetron - StatPearls - NCBI Bookshelf - NIH Feb 15, 2023 — ondansetron dose ped
For children unable to swallow tablets, ondansetron is available in orally disintegrating tablets (ODT) and liquid solutions. It is worth noting that the bioavailability of oral ondansetron is approximately 60%, necessitating adjustments if converting to intravenous routes. Here is the clinical content regarding